Immune Checkpoint Blockade in Hepatocellular Carcinoma.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

17 citing papers in PubMed.

1. Dual Immune Checkpoint Blockade in Synchronous Hepatocellular and Renal Cell Carcinoma: A Real-World Case Report of Durable Dual Response.Oncology research · 2026
   Article
2. Experimental study of iodine-131 labeling of a novel tumor-targeting peptide, TFMP-Y4, in the treatment of hepatocellular carcinoma with internal irradiation.BMC cancer · 2025
   Article
3. Syngeneic N1-S1 Orthotopic Hepatocellular Carcinoma in Sprague Dawley Rat for the Development of Interventional Oncology-Based Immunotherapy: Survival Assay and Tumor Immune Microenvironment.Cancers · 2023
   Article
4. Combination of interventional oncology local therapies and immunotherapy for the treatment of hepatocellular carcinoma.Journal of liver cancer · 2022
   Review
5. Noncoding RNA-mediated molecular bases of chemotherapy resistance in hepatocellular carcinoma.Cancer cell international · 2022
   Review
6. Therapy in Advanced Hepatocellular Carcinoma.Seminars in interventional radiology · 2020
   Review
7. High Blood miR-802 Is Associated With Poor Prognosis in HCC Patients by Regulating DNA Damage Response 1 (REDD1)-Mediated Function of T Cells.Oncology research · 2019
   Article
8. [Advances in the study of programmed cell death protein 1 and its ligand inhibitors in the treatment of late stage HCC].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2019
   Review
9. From NASH to HCC: current concepts and future challenges.Nature reviews. Gastroenterology & hepatology · 2019
   Review
10. Identification of α-fetoprotein-specific T-cell receptors for hepatocellular carcinoma immunotherapy.Hepatology (Baltimore, Md.) · 2018
    Article
11. CLEC1B Expression and PD-L1 Expression Predict Clinical Outcome in Hepatocellular Carcinoma with Tumor Hemorrhage.Translational oncology · 2018
    Article
12. How does the tumor microenvironment play a role in hepatobiliary tumors?Journal of gastrointestinal oncology · 2018
    Review
13. Neutrophils: driving progression and poor prognosis in hepatocellular carcinoma?British journal of cancer · 2018
    Article
14. B7-H4 overexpression is essential for early hepatocellular carcinoma progression and recurrence.Oncotarget · 2017
    Article
15. Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses.Proceedings of the National Academy of Sciences of the United States of America · 2017
    Article
16. Immune Checkpoint Blockade in Hepatocellular Carcinoma: 2017 Update.Liver cancer · 2016
    Article
17. Challenges of advanced hepatocellular carcinoma.World journal of gastroenterology · 2016
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.